logo

APRE

Aprea Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.14 / 10
Netural

With a fund flow rating of 7.54/10, the stock shows robust fund flow characteristics. Supportive momentum from overall, block, Large, and Extra-large trends is partially offset by concerning Small and Medium patterns, pointing to positive capital flow trajectory. Research analyst consensus shows overwhelmingly bullish analyst consensus, demonstrating strong conviction. Current ratings: Strong Buy(100.0%) across 1 coverage providers, supported by 2.75 historical weighted rating.

FundamentalSentiment(5.14)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2026-01-29
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
Is money flowing into or out of APRE?
  • APRE holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.14/10 (Netural).